Equities research analysts expect Arcadia Biosciences Inc (NASDAQ:RKDA) to announce sales of $450,000.00 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Arcadia Biosciences’ earnings. The lowest sales estimate is $400,000.00 and the highest is $500,000.00. Arcadia Biosciences posted sales of $440,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 2.3%. The company is expected to issue its next earnings report on Wednesday, March 25th.
On average, analysts expect that Arcadia Biosciences will report full-year sales of $1.15 million for the current fiscal year, with estimates ranging from $1.10 million to $1.20 million. For the next year, analysts anticipate that the firm will report sales of $8.55 million, with estimates ranging from $6.30 million to $10.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Arcadia Biosciences.
Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings data on Wednesday, November 6th. The basic materials company reported ($2.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($1.27). The firm had revenue of $0.39 million during the quarter, compared to analyst estimates of $0.31 million. Arcadia Biosciences had a negative net margin of 1,938.76% and a negative return on equity of 198.10%.
Shares of RKDA stock traded up $0.21 during mid-day trading on Friday, reaching $5.42. The stock had a trading volume of 172,571 shares, compared to its average volume of 1,262,908. The business’s fifty day moving average is $4.76 and its 200-day moving average is $4.68. The company has a current ratio of 5.58, a quick ratio of 5.27 and a debt-to-equity ratio of 0.11. The firm has a market cap of $45.15 million, a price-to-earnings ratio of -1.01 and a beta of -2.98. Arcadia Biosciences has a 1-year low of $1.82 and a 1-year high of $10.40.
In other news, Director Kevin Comcowich acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were acquired at an average cost of $5.88 per share, with a total value of $29,400.00. Following the completion of the acquisition, the director now owns 20,000 shares of the company’s stock, valued at $117,600. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders bought 32,200 shares of company stock worth $188,076 over the last three months. Corporate insiders own 3.30% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new stake in Arcadia Biosciences during the second quarter worth about $32,000. Cambridge Investment Research Advisors Inc. acquired a new stake in Arcadia Biosciences during the second quarter worth about $34,000. Squarepoint Ops LLC purchased a new position in Arcadia Biosciences during the third quarter worth approximately $124,000. Sabby Management LLC boosted its position in Arcadia Biosciences by 150.0% during the third quarter. Sabby Management LLC now owns 50,000 shares of the basic materials company’s stock worth $234,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Morgan Stanley boosted its position in Arcadia Biosciences by 162,800.0% during the second quarter. Morgan Stanley now owns 81,450 shares of the basic materials company’s stock worth $250,000 after purchasing an additional 81,400 shares in the last quarter. 8.03% of the stock is currently owned by hedge funds and other institutional investors.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.